Sun Pharma loses bid to drop Ranbaxy antitrust case; jury trail set for January

When Sun Pharma acquired troubled Ranbaxy in 2014 for $4 billion, the India generics giant knew it was inheriting some major compliance problems. At the time, four of Ranbaxy’s five plants were sidelined by the FDA.